Targeting DDR2 enhances tumor response to anti–PD-1 immunotherapy

While a fraction of cancer patients treated with anti–PD-1 show durable therapeutic responses, most remain unresponsive, highlighting the need to better understand and improve these therapies. Using an in vivo screening approach with a customized shRNA pooled library, we identified DDR2 as a leading...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Adv
Egile Nagusiak: Tu, Megan M., Lee, Francis Y. F., Jones, Robert T., Kimball, Abigail K., Saravia, Elizabeth, Graziano, Robert F., Coleman, Brianne, Menard, Krista, Yan, Jun, Michaud, Erin, Chang, Han, Abdel-Hafiz, Hany A., Rozhok, Andrii I., Duex, Jason E., Agarwal, Neeraj, Chauca-Diaz, Ana, Johnson, Linda K., Ng, Terry L., Cambier, John C., Clambey, Eric T., Costello, James C., Korman, Alan J., Theodorescu, Dan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Association for the Advancement of Science 2019
Gaiak:
Research Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6382401/
https://ncbi.nlm.nih.gov/pubmed/30801016
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1126/sciadv.aav2437
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak